S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:SPHSSophiris Bio Stock Price, Forecast & News

$0.01
+0.00 (+10.58 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$1.07
Volume208,807 shs
Average Volume448,072 shs
Market Capitalization$408,825.00
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Read More
Sophiris Bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-6,780,000.00

Miscellaneous

Employees6
Market Cap$408,825.00
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable
$0.01
+0.00 (+10.58 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

How has Sophiris Bio's stock been impacted by COVID-19 (Coronavirus)?

Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPHS stock has decreased by 95.0% and is now trading at $0.0115.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Sophiris Bio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sophiris Bio
.

When is Sophiris Bio's next earnings date?

Sophiris Bio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Sophiris Bio
.

How were Sophiris Bio's earnings last quarter?

Sophiris Bio Inc (NASDAQ:SPHS) released its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02.
View Sophiris Bio's earnings history
.

What price target have analysts set for SPHS?

1 brokers have issued 12 month target prices for Sophiris Bio's stock. Their forecasts range from $2.80 to $2.80. On average, they anticipate Sophiris Bio's stock price to reach $2.80 in the next year. This suggests a possible upside of 24,247.8% from the stock's current price.
View analysts' price targets for Sophiris Bio
.

Has Sophiris Bio been receiving favorable news coverage?

News stories about SPHS stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sophiris Bio earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Sophiris Bio
.

Who are some of Sophiris Bio's key competitors?

What other stocks do shareholders of Sophiris Bio own?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the following people:
  • Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
  • Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
  • Mr. Peter T. Slover, Chief Financial Officer (Age 44)
  • Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
  • Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.01.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $408,825.00. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is www.sophirisbio.com.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.